Drs. H. Jack West, Medical Director - Thoracic Oncology Program at Swedish Cancer Institute, President and CEO of GRACE, Karen Kelly - Associate...
ASCO 2018 Roundtable - Lung Cancer - Keynote 042 Trial - Keytruda (Pembrolizumab) as a Single Agent Compared to Doublet Chemotherapy for NSCLC
Dr. H. Jack West, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, President and CEO of GRACE offers updates to our Lung Cancer...
Case Based Panel Discussion - Advanced Non Squamous NSCLC, High PD-L1, No Driver Mutation - What is the Optimal 1st Line?
Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss the optimal 1st line treatment for a patient with advanced non squamous non small cell lung cancer, high PD-L1, and no driver mutation.
Case Based Panel Discussion - Advanced Non Squamous NSCLC, Low PD-L1 No Driver Mutation - Is There a Best Systemic Therapy Option?
Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss if there is a best systemic therapy option for a patient with advanced non-squamous NSCLC, low PD-L1 and no driver mutation.
Case Based Panel Discussion - What is the Optimal Approach for a Fit Patient with Advanced Squamous NSCLC and Low Tumor PD-L1 Expression
Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss the optimal approach for a fit patient with advanced squamous NSCLC and low tumor PD-L1 expression.
- 1 of 5
- View More
Download slides from LIVE WEBCAST of November 18, 2017 in partnership with Georgetown University Hospital, GRACE presents: 2017 Advances in Immunotherapy: What Lung Cancer Patients Need to Know
Imprecision Medicine: Why Keytruda (Pembrolizumab) + Chemo for PD-L1+ NSCLC isn't Ready for Prime Time
Let me start by saying that I'm a fan of the immune checkpoint inhibitor Keytruda (pembrolizumab) and consider it the new standard of care as a...
First Line Immunotherapy for Advanced Non-Small Cell Lung Cancer: A Great Option for Some, but Not for All
Several weeks ago, at a very crowded plenary session for the European Society of Medical Oncology (ESMO) in Copenhagen, Denmark, results with first...
Among the many novel concepts in managing immunotherapy is the potential for “pseudo-progression”. This unusual phenomenon is when a patient’s scans...
Keytruda (Pembrolizumab) Beats Chemo as First Line Therapy for Patients with High Tumor Expression of PD-L1: Where are We Now?
It seemed inevitable, I think. Several immuntherapy agents known as PD-1 or PD-L1 checkpoint inhibitors have been shown to lead to better survival,...
- 1 of 2
- View More
Hi Grace Members, Grace is happy to present in partnership with the Swedish Cancer Institute " Local Therapies for Metastatic Lung Cancer Who,...
Progression after 3 1/2 years on Tarceva. Tissue biopsy showed T790m negative. Any suggestions/experience on next steps? Onc suggesting I move to Afatinib or a Opdivo. PDL1 was tested and is <1%.
Hello friends, My mom, (aged 77, Adenocarcinoma NSCLC, Stage 4, EGFR and ALK negative) was diagnosed in 2014, underwent VATS and pleurodesis,...